A total of 1733 ocular adverse event reports were identified from the FDA database, with 1541 linked to subcutaneous semaglutide and 192 to oral semaglutide.
Most adverse events occurred within the first month of treatment, with median times to onset of 7.00 days for injectables and 3.50 days for tablets.
5.41% of patients using subcutaneous semaglutide and 2.17% of those on oral semaglutide reported after one year.
Female patients showed a higher susceptibility to ocular adverse reactions than male patients.
Blurred vision was the most common adverse event associated with oral semaglutide, accounting for 34.33% of the reports.
Subcutaneous semaglutide was linked to a higher frequency of specific retinal complications compared to oral semaglutide.
Simplified
BACKGROUND: This study systematically compares the risk of long-term between subcutaneous and oral semaglutide preparations to assess pathway-specific safety differences.
METHODS: In this study, the Report odds ratio (ROR) technique was employed to detect signals of adverse drug reactions (ADRs) associated with the use of semaglutide. Analysis was conducted on data extracted from the FDA Adverse Event Reporting System (FAERS) database, covering the period from 2004(Q1) through 2024(Q3). This investigation encompasses a descriptive analysis focused on the administration of semaglutide through various routes, encompassing a broad range of demographics including gender (male and female), age groups, along with other demographic data and the timing of disease onset. Following this, the study employs the ROR methodology to assess the differential adverse event signals across distinct semaglutide formulations.
RESULTS: We categorized the eye as the System Organ Class (SOC) and obtained 1733 ADE reports related to it from the FAERS database. Of these, 1541 reports were associated with injectables, while tablets were linked to 192 ADE reports. In both dosage forms, most cases occurred within the first month of administration, although the median time to onset (TTO) differed, with injectables identified at 7.00 [IQR 0.00-56.00] days and tablets at only 3.50 [IQR 0.00-35.00] days. It is worth noting that 5.41% of patients administered subcutaneous injections and 2.17% of those receiving oral medications reported ADEs following one year of treatment with semaglutide. Furthermore, female patients exhibited a higher susceptibility to ocular adverse reactions compared to their male counterparts. Regarding the primary preferred terms (PTs), blurred vision constitutes 34.33% of the total ADEs associated with tablet formulations. This incidence is marginally higher than that observed with injectable formulations. This investigation further discerned ocular ADEs signals associated with specific formulations: subcutaneous injections have a higher frequency of reports concerning retinal complications, such as diabetic retinopathy, ischemic optic neuropathy, retinal detachment, retinal tear, and retinal hemorrhage.
CONCLUSION: The results of this study identified a significant difference between subcutaneous and oral semaglutide in ocular ADE risk, providing some evidence for dosage form selection and risk monitoring for clinical use.
Key numbers
1541 vs. 192
Ocular ADE Reports ( vs. )
Total ocular ADE reports from for each dosage form.
34.33%
Blurred Vision Incidence
Percentage of blurred vision cases among semaglutide .
62.72%
Female ADE Reporting Rate
Proportion of ocular ADE reports from female patients.
Full Text
We can’t show the full text here under this license.
Declarations. Ethics approval and consent to participate: This article is based on open-label data and does not contain any new studies conducted by authors on human participants or animals and does not require ethical approval. All the study participants provided their informed consent since there is no personal data, publication consent is not requested. Competing interests: The authors declare no competing interests.
